Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2022)

Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

Lantheus Holdings (NASDAQ:LNTH) is the top diagnostic & research stock with a Zen Score of 59, which is 28 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock return 108.34% over the past year, overperforming other diagnostic & research stocks by 133 percentage points.

Lantheus Holdings has an average 1 year price target of $107.25, an upside of 93.31% from Lantheus Holdings's current stock price of $55.48.

Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Lantheus Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Sotera Health Co (NASDAQ:SHC) is the second best diagnostic & research stock with a Zen Score of 58, which is 27 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -61.03% over the past year, underperforming other diagnostic & research stocks by -37 percentage points.

Sotera Health Co has an average 1 year price target of $13.56, an upside of 60.62% from Sotera Health Co's current stock price of $8.44.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 20% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 30% have issued a Strong Sell.

Syneos Health (NASDAQ:SYNH) is the third best diagnostic & research stock with a Zen Score of 56, which is 25 points higher than the diagnostic & research industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -65.5% over the past year, underperforming other diagnostic & research stocks by -41 percentage points.

Syneos Health has an average 1 year price target of $52.29, an upside of 53.15% from Syneos Health's current stock price of $34.14.

Syneos Health stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.79%, which is 5 percentage points higher than the diagnostic & research industry average of 1.95%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

Psychemedics (NASDAQ:PMD) has an annual dividend yield of 4.59%, which is 3 percentage points higher than the diagnostic & research industry average of 1.95%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -52.8% indicates that its high dividend yield might not be sustainable for the long-term.

National Research (NASDAQ:NRC) has an annual dividend yield of 2.14%, which is the same as the diagnostic & research industry average of 1.95%. National Research's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. National Research's dividend has shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 60.4% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were down -1% in the last day, and up 0.92% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -61.03% in the past year. It has underperformed other stocks in the diagnostic & research industry by -37 percentage points.

Quidelortho (NASDAQ:QDEL) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -34.01% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

Syneos Health (NASDAQ:SYNH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -65.5% in the past year. It has underperformed other stocks in the diagnostic & research industry by -41 percentage points.